截至9月30日，华宝股份股东户数1.53万，较上期减少12.93%；人均流通股40206股，较上期增加 14.85%。2025年1月-9月，华宝股份实现营业收入9.96亿元，同比减少7.21%；归母净利润7702.86万元， 同比减少57.00%。 分红方面，华宝股份A股上市后累计派现67.25亿元。近三年，累计派现11.21亿元。 2月2日，华宝股份跌3.94%，成交额9327.33万元。两融数据显示，当日华宝股份获融资买入额619.32万 元，融资偿还828.90万元，融资净买入-209.58万元。截至2月2日，华宝股份融资融券余额合计1.26亿 元。 融资方面，华宝股份当日融资买入619.32万元。当前融资余额1.26亿元，占流通市值的1.10%，融资余 额超过近一年60%分位水平，处于较高位。 融券方面，华宝股份2月2日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量2.63万股，融券余额48.76万元，超过近一年90%分位水平，处于高位。 资料显示，华宝香精股份有限公司位于上海市嘉定区叶城路1299号，成立日期1996年6月27日，上市日 期2018年3月1日 ...

Core Viewpoint - Huabao Co., Ltd. (300741.SZ) expects a net profit attributable to shareholders of 65 million to 95 million yuan for 2025, marking a turnaround from losses in the previous year [1] Financial Performance - The company reported a net profit turnaround for the period, with a projected net profit of 65 million to 95 million yuan for 2025, compared to losses in 2024 [1] - The losses in 2024 were primarily due to goodwill impairment losses related to the flavoring and tobacco flavoring asset group [1] Business Outlook - The overall operating conditions of the company are expected to remain stable in 2025, with orderly development of the main business and continuous optimization of internal management [1] - Management's preliminary assessment indicates that there is no significant risk of further major goodwill impairment as of December 31, 2025 [1]

Group 1 - The core viewpoint of the article is that Huabao Co., Ltd. expects to achieve a net profit of between 65 million and 95 million yuan for the fiscal year 2025, indicating a turnaround from previous losses [2] Group 2 - The announcement was made on January 28, highlighting the company's optimistic outlook for profitability in the upcoming fiscal year [2]

报告期内，华宝股份实现归属于上市公司股东的净利润扭亏为盈。2024年度，华宝股份业绩亏损主要由于食用香精-烟草用香精相关资产组计提商誉减值损 失。2025年度，华宝股份整体经营情况保持稳定，主营业务有序开展，内部管理持续优化，经管理层初步评估，于2025年12月31日，华宝股份商誉不存在进 一步重大减值风险。 智通财经APP讯，华宝国际(00336)发布附属公司华宝香精股份有限公司(华宝股份)(300741.SZ)截至2025年1月1日至2025年12月31日止年度业绩，归属于华宝 股份股东的净利润为6500-9500万，上年同期亏损约2.96亿元;扣除非经常性损益后的净利润6500-9500万元，上年同期亏损约3.86亿元。 ...

华宝股份1月28日发布业绩预告，预计2025年净利润6500万元-9500万元，同比扭亏为盈，上年同期亏损 2.96亿元。2024年度，公司业绩亏损主要由于食用香精-烟草用香精相关资产组计提商誉减值损失。 2025年度，公司整体经营情况保持稳定，主营业务有序开展，内部管理持续优化，经管理层初步评估， 于2025年12月31日，公司商誉不存在进一步重大减值风险。 ...

Core Viewpoint - Huabao International (00336) reported that its subsidiary, Huabao Flavors & Fragrances Co., Ltd. (300741.SZ), is expected to achieve a net profit of 65-95 million for the fiscal year ending December 31, 2025, a significant recovery from a loss of approximately 296 million in the previous year [1] Financial Performance - The net profit attributable to Huabao Flavors' shareholders is projected to be between 65 million and 95 million, compared to a loss of about 296 million in the same period last year [1] - The net profit after deducting non-recurring gains and losses is also expected to be between 65 million and 95 million, with a prior year loss of approximately 386 million [1] Operational Insights - During the reporting period, Huabao Flavors successfully turned a profit, reversing previous losses [1] - The losses in 2024 were primarily due to goodwill impairment losses related to the edible flavor and tobacco flavor asset group [1] - For 2025, the overall operational situation of Huabao Flavors is expected to remain stable, with orderly development of its main business and continuous optimization of internal management [1] - Management's preliminary assessment indicates that there is no significant risk of further impairment of goodwill as of December 31, 2025 [1]

Financial Projections - The estimated net profit for 2025 is projected to be between 65 million and 95 million RMB, indicating a turnaround from a loss of approximately 296.34 million RMB in the previous year[4] - The net profit after deducting non-recurring gains and losses is also expected to be between 65 million and 95 million RMB, compared to a loss of about 386.18 million RMB last year[4] Operational Stability - The overall operational situation of the company is stable, with main business activities proceeding in an orderly manner and ongoing internal management optimization[6] - Management has preliminarily assessed that there is no significant risk of further major impairment of goodwill as of December 31, 2025[6] Previous Losses - The company attributes the previous year's losses primarily to goodwill impairment losses related to the flavoring segment for tobacco[6] Financial Data and Risks - The financial data provided in the earnings forecast is preliminary and has not yet been audited by the accounting firm[5] - The company emphasizes the importance of cautious decision-making and awareness of investment risks for investors[7]

Core Insights - The groundbreaking ceremony for Huabao's "Jia Cui Biological Jinan Health Industry Base Project" took place on January 19, 2026, marking the start of a modern production base aimed at upgrading the health food industry [1][10]. Group 1: Strategic Importance - The Jinan Health Industry Base project aligns with the "Healthy China 2030" strategic plan, representing a key initiative for Huabao to deepen its involvement in the health industry and expand its functional food ingredient portfolio [1][10]. - The project is viewed as a "model project" for Huabao's health industry layout, emphasizing the importance of "North-South collaboration and comprehensive layout" strategies [3][11]. Group 2: Project Development and Goals - The project aims to transition the industry from "manufacturing" to "intelligent manufacturing," ensuring high-speed, high-quality, and efficient construction [5][13]. - Future collaboration with partners will focus on exploring diverse cooperation paths in the health food sector, aiming for mutual benefits and value enhancement [3][11]. Group 3: Commitment to Innovation - Shanghai Jia Cui is committed to its core mission of making food healthier, nutrition tastier, and functionality more efficient, with the Jinan base serving as a new starting point for expanding into the northern market and enhancing regional service networks [9][14]. - The company plans to leverage modern production capabilities to strengthen technological innovation and quality control, contributing to the establishment of an open, collaborative, and innovation-driven health industry ecosystem [9][14].

Group 1 - The core point of the article is that Huabao Co., Ltd. has confirmed its goodwill book value as of September 30, 2025, to be 718 million yuan [2] - The company will conduct a goodwill impairment test at the end of the year in accordance with accounting standards, and the results will determine whether to recognize impairment and the amount [2] - Huabao Co., Ltd. emphasizes its commitment to compliance and ensuring that information disclosure is truthful, accurate, and complete, with detailed financial data and impairment situations to be disclosed in the 2025 annual report [2]

Core Viewpoint - The company emphasizes its commitment to legal compliance and adherence to national laws, accounting standards, and regulatory requirements for listed companies [1] Group 1 - The company responds to investor inquiries on its interactive platform, reinforcing its dedication to lawful operations [1] - The company urges investors to rely on its information disclosures for rational investment decisions [1] - The company commits to timely information disclosure in accordance with regulatory requirements for any matters that need to be disclosed [1]